EXICURE, INC. (XCUR): Nasdaq/NYSE listing notice — Exicure receives Nasdaq delisting notice for board independence; director resigns

EXICURE, INC.

Jan 19, 2023: Nasdaq notifies Exicure of non-compliance with Listing Rule 5605 (independent director/audit committee requirements). Cure period ends at earlier of 2023 annual meeting or Dec 30, 2023.
Director Jiyoung Hwang resigned effective Jan 16, 2023; no disagreement with company operations, policies, or practices.
Company actively seeking qualified independent director to regain compliance; must comply by June 28, 2023 if annual meeting before that date.
Private placement of 3,400,000 shares at $1.60/share with CBI USA expected to close by Feb 10, 2023 (previously disclosed Sep 26, 2022).

item 3.01 item 5.02 item 7.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jiyoung Hwang

Director

XCUR · EXICURE, INC.

Effective: 2023-01-16
Filed: January 20, 2023, 6:59 PM ET

On January 16, 2023, Jiyoung Hwang tendered her resignation from the Board, effective immediately as of such date.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

EXICURE, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(b)(1)(A), 5605(c)(4)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605, 5605(b)(1)(A), 5605(c)(4)

Exact text from the filing

January 19, 2023, Exicure, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is no longer in compliance with Nasdaq’s independent director and audit committee requirements as set forth in Nasdaq Listing Rule 5605, which requires the board of directors to be comprised of a majority of independent directors and the audit committee of the board of directors to be comprised of three independent directors (the “Listing Requirement”). Pursuant to Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4), the Company is entitled to a cure period to regain compl

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jiyoung Hwang resigned as Director at EXICURE, INC..

Action: resigned
Role: Director

Exact text from the filing

On January 16, 2023, Jiyoung Hwang tendered her resignation from the Board, effective immediately as of such date.

View on SEC.gov

Browse all listing & compliance notices →

EXICURE, INC. filing history →

Source: SEC EDGAR

accession 0001698530-23-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.